Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Novartis Says 6-Year Kisqali Data Show Overall Survival Benefit in Early Breast Cancer

Novartis Says 6-Year Kisqali Data Show Overall Survival Benefit in Early Breast Cancer

MT newswireMT newswire2026/10/23 12:30
08:30 AM EDT, 10/23/2026 (MT Newswires) -- Novartis (NVS) said Friday that six-year data from a phase 3 trial showed Kisqali plus endocrine therapy reduced the risk of death by 19.1%, compared with endocrine therapy alone, in patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. The combination therapy delivered an overall survival hazard ratio of 0.809, while the absolute invasive disease-free survival benefit rose to 5.3% at six years from 4.1% at five years, and the overall survival benefit widened to 2.1% from 1.2%, the company said. The six-year data also showed a roughly 30% lower risk of breast cancer-specific death, with benefits persisting for a median of 38 months after patients stopped Kisqali, Novartis said. No new safety signals were observed, the company added.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korean think tanks significantly raise 2027 economic growth forecasts, betting on continued AI chip boom

The Korea Development Institute (KDI) raised its economic growth forecast for this year and next on Wednesday, betting that the global artificial intelligence (AI) boom will continue to drive semiconductor exports and investment, helping the South Korean economy maintain its growth momentum.

智通财经•2026/11/18 04:12

SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”

SQM.US still reports seeing "encouraging" potential demand trends.

智通财经•2026/11/18 03:16

Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.

According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

智通财经•2026/11/18 03:07
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years

Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.

智通财经•2026/11/18 03:02
Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years